Advances and novel developments in drug hypersensitivity diagnosis.
In vivo tests
diagnosis
drug hypersensitivity
in vitro tests
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
08
05
2020
revised:
16
09
2020
accepted:
17
09
2020
pubmed:
30
9
2020
medline:
15
5
2021
entrez:
29
9
2020
Statut:
ppublish
Résumé
A correct diagnosis of drug hypersensitivity reactions (DHRs) is very important for both the patient and health system. However, DHRs diagnosis is complex, time consuming, requires trained personnel, is not standardized for many drugs, involves procedures not exempt of risk, and in most cases lacks standardized in vivo and in vitro tests. Thus, there is an urgent need for improving the different approaches to diagnose patients with suspected DHRs. In this review, we have analyzed the advances performed in immediate and nonimmediate DHRs diagnosis during the last two years and obtained several conclusions: the significant heterogeneity in current practice among centers illustrates the need to re-evaluate, update, and standardize in vivo tests and protocols for the diagnosis and management of patients with suspected drug allergy. Regarding in vitro tests, the latest studies have focused on increasing their sensitivity or on establishing the sensitivity and specificity for the tests performed with new drugs. There seems to be a consensus about combining in vivo and in vitro tests as the best way to increase the diagnostic accuracy.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3112-3123Informations de copyright
© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Références
Tanno LK, Torres MJ, Castells M, Demoly P, Joint AA. What can we learn in drug allergy management from World Health Organization's international classifications? Allergy. 2018;73(5):987-992.
Sousa-Pinto B, Blumenthal KG, Macy E, et al. Diagnostic testing for penicillin allergy: a survey of practices and cost perceptions. Allergy. 2020;75(2):436-441.
Romano A, Atanaskovic-Markovic M, Barbaud A, et al. Towards a more precise diagnosis of hypersensitivity to beta-lactams - an EAACI position paper. Allergy. 2020;75(6):1300-1315.
Atanasković-Marković M, Janković J, Tmušić V, et al. Hypersensitivity reactions to antiepileptic drugs in children. Pediatr Allergy Immunol. 2019;30(5):547-552.
Braun C, Reix P, Durieu I, et al. The diagnosis of hypersensitivity to antibiotics is rarely confirmed by allergy work-up in cystic fibrosis patients. Pediatr Allergy Immunol. 2020;31(4):396-404.
Khaleva E, Franz A, Garvey LH, et al. Perioperative anaphylaxis in children: Etiology, time sequence, and patterns of clinical reactivity. Pediatr Allergy Immunol. 2020;31(1):85-94.
Torres MJ, Romano A, Celik G, et al. Approach to the diagnosis of drug hypersensitivity reactions: similarities and differences between Europe and North America. Clin Transl Allergy. 2017;7:7.
Demoly P, Adkinson NF, Brockow K, et al. International Consensus on drug allergy. Allergy. 2014;69(4):420-437.
Brockow K, Ardern-Jones MR, Mockenhaupt M, et al. EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. Allergy. 2019;74(1):14-27.
Ojeda P, Sastre J, Olaguibel JM, Chivato T, Investigators participating in the National Survey of the Spanish Society of A, Clinical Immunology A. Alergologica 2015: A National Survey on Allergic Diseases in the Adult Spanish Population. J Investig Allergol Clin Immunol. 2018;28(3):151-164.
Pichler WJ. Immune pathomechanism and classification of drug hypersensitivity. Allergy. 2019;74(8):1457-1471.
Garvey LH, Dewachter P, Hepner DL, et al. Management of suspected immediate perioperative allergic reactions: an international overview and consensus recommendations. Br J Anaesth. 2019;123(1):e50-e64.
Brockow K. Medical algorithm: diagnosis and treatment of radiocontrast media hypersensitivity. Allergy. 2020;75(5):1278-1280.
Hopkins PM, Cooke PJ, Clarke RC, et al. Consensus clinical scoring for suspected perioperative immediate hypersensitivity reactions. Br J Anaesth. 2019;123(1):e29-e37.
Chiriac AM, Banerji A, Gruchalla RS, et al. Controversies in drug allergy: drug allergy pathways. J Allergy Clin Immunol Pract. 2019;7(1):46-60.e44.
Lin CC, Chen CB, Wang CW, Hung SI, Chung WH. Stevens-Johnson syndrome and toxic epidermal necrolysis: risk factors, causality assessment and potential prevention strategies. Expert Rev Clin Immunol. 2020;16(4):373-387.
Brockow K, Garvey LH, Aberer W, et al. Skin test concentrations for systemically administered drugs - an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2013;68(6):702-712.
Torres MJ, Celik GE, Whitaker P, et al. A EAACI drug allergy interest group survey on how European allergy specialists deal with beta-lactam allergy. Allergy. 2019;74(6):1052-1062.
Garvey LH, Ebo DG, Mertes P-M, et al. An EAACI position paper on the investigation of perioperative immediate hypersensitivity reactions. Allergy. 2019;74(10):1872-1884.
Gonzalez-Estrada A, Archibald T, Dinsmore K, Mosier G, Campbell B, Brown S. Stability of diluted neuromuscular blocking agents utilized in perioperative hypersensitivity evaluation. Allergy. 2018;73(12):2398-2400.
Kepil Özdemir S, Gelincik A, Paksoy N, et al. Analysis of the factors associated with diagnostic skin test positivity in immediate-type hypersensitivity reactions due to proton pump inhibitors. Allergy. 2019;74(6):1187-1190.
Lezmi G, Alrowaishdi F, Bados-Albiero A, Scheinmann P, de Blic J, Ponvert C. Non-immediate-reading skin tests and prolonged challenges in non-immediate hypersensitivity to beta-lactams in children. Pediatr Allergy Immunol. 2018;29(1):84-89.
Yang M-S, Kang DY, Seo B, et al. Incidence of cephalosporin-induced anaphylaxis and clinical efficacy of screening intradermal tests with cephalosporins: a large multicenter retrospective cohort study. Allergy. 2018;73(9):1833-1841.
Cabanas R, Ramirez E, Sendagorta E, et al. Spanish guidelines for diagnosis, management, treatment and prevention of DRESS syndrome. J Investig Allergol Clin Immunol. 2020;30(4):229-253..
Trubiano JA, Douglas AP, Goh M, Slavin MA, Phillips EJ. The safety of antibiotic skin testing in severe T-cell-mediated hypersensitivity of immunocompetent and immunocompromised hosts. J Allergy Clin Immunol Pract. 2019;7(4):1341-1343.
Phillips EJ, Bigliardi P, Bircher AJ, et al. Controversies in drug allergy: testing for delayed reactions. J Allergy Clin Immunol. 2019;143(1):66-73.
Pasteur J, Favier L, Pernot C, et al. Low cross-reactivity between cisplatin and other platinum salts. J Allergy Clin Immunol Pract. 2019;7(6):1894-1900.
Kwon OY, Lee J-H, Park S-Y, et al. Novel strategy for the prevention of recurrent hypersensitivity reactions to radiocontrast media based on skin testing. J Allergy Clin Immunol Pract. 2019;7(8):2707-2713.
Trautmann A, Brockow K, Behle V, Stoevesandt J. Radiocontrast media hypersensitivity: skin testing differentiates allergy from nonallergic reactions and identifies a safe alternative as proven by intravenous provocation. J Allergy Clin Immunol Pract. 2019;7(7):2218-2224.
Petitpain N, Argoullon L, Masmoudi K, et al. Neuromuscular blocking agents induced anaphylaxis: results and trends of a French pharmacovigilance survey from 2000 to 2012. Allergy. 2018;73(11):2224-2233.
Gracia-Bara MT, Moreno E, Laffond E, et al. Tolerability of iobitridol in patients with non-immediate hypersensitivity reactions to iodinated contrast media. Allergy. 2019;74(1):195-197.
Kidon M, Blanca-Lopez N, Gomes E, et al. EAACI/ENDA Position Paper: Diagnosis and management of hypersensitivity reactions to non-steroidal anti-inflammatory drugs (NSAIDs) in children and adolescents. Pediatr Allergy Immunol. 2018;29(5):469-480.
Van Thuijl AOJ, Landzaat LJ, Liem O, Emons JAM, Arends NJT. Drug-induced enterocolitis syndrome (DIES): A clinical entity that deserves more awareness. Ann Allergy Asthma Immunol. 2019;122(5):538-539.
Freundt Serpa NP, Sánchez-Morillas L, Jaqueti Moreno P, et al. Drug-induced enterocolitis syndrome due to amoxicillin-clavulanic acid with good tolerance to penicillin. J Investig Allergol Clin Immunol. 2020;30(4):301-302.
Landry Q, Zhang S, Ferrando L, Bourrain JL, Demoly P, Chiriac AM. Multiple Drug Hypersensitivity Syndrome in a Large Database. J Allergy Clin Immunol Pract. 2020;8(1):258-266.e251.
Jorg L, Yerly D, Pichler W. Multiple drug hypersensitivity syndrome (MDH) should not be diagnosed by drug provocation tests. J Allergy Clin Immunol Pract. 2020;8(2):822-823.
Kowalski ML, Agache I, Bavbek S, et al. Diagnosis and management of NSAID-exacerbated respiratory disease (N-ERD)-a EAACI position paper. Allergy. 2019;74(1):28-39.
Laidlaw TM, Levy JM. NSAID-ERD syndrome: the new hope from prevention, early diagnosis, and new therapeutic targets. Curr Allergy Asthma Rep. 2020;20(4):10.
Dona I, Perez-Sanchez N, Bogas G, Moreno E, Salas M, Torres MJ. Medical algorithm: diagnosis and treatment of nonsteroidal antiinflammatory drugs hypersensitivity. Allergy. 2020;75(4):1003-1005.
Doña I, Pérez-Sánchez N, Eguiluz-Gracia I, et al. Progress in understanding hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Allergy. 2020;75(3):561-575.
Izquierdo-Domínguez A, Bobolea I, Doña I, et al. Statement of the Spanish Society of Allergology and Clinical Immunology on Provocation Tests With Aspirin/Nonsteroidal Anti-inflammatory Drugs. J Investig Allergol Clin Immunol. 2020;30(1):1-13.
Madrigal-Burgaleta R, Bernal-Rubio L, Berges-Gimeno MP, Carpio-Escalona LV, Gehlhaar P, Alvarez-Cuesta E. A large single-hospital experience using drug provocation testing and rapid drug desensitization in hypersensitivity to antineoplastic and biological agents. J Allergy Clin Immunol Pract. 2019;7(2):618-632.
Garvey LH, Savic LC. Drug provocation testing: risk stratification is key. Curr Opin Allergy Clin Immunol 2019;19(4):266-271.
Aberer W, Bircher A, Romano A, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy. 2003;58(9):854-863.
Laguna JJ, Archilla J, Doña I, et al. Practical guidelines for perioperative hypersensitivity reactions. J Investig Allergol Clin Immunol. 2018;28(4):216-232.
Garvey LH, Ebo DG, Krøigaard M, et al. The use of drug provocation testing in the investigation of suspected immediate perioperative allergic reactions: current status. Br J Anaesth. 2019;123(1):e126-e134.
Bergmann MM, Caubet JC. Role of in vivo and in vitro Tests in the Diagnosis of Severe Cutaneous Adverse Reactions (SCAR) to Drug. Curr Pharm Des. 2019;25(36):3872-3880.
Kulhas Celik I, Guvenir H, Hurmuzlu S, et al. The negative predictive value of 5-day drug provocation test in nonimmediate beta-lactam allergy in children. Ann Allergy Asthma Immunol. 2020;124(5):494-499.
Siew LQC, Li PH, Watts TJ, et al. Identifying low-risk beta-lactam allergy patients in a UK Tertiary Centre. J Allergy Clin Immunol Pract. 2019;7(7):2173-2181.
Garcia Rodriguez R, Moreno Lozano L, Extremera Ortega A, Borja Segade J, Galindo Bonilla P, Gomez TE. Provocation tests in nonimmediate hypersensitivity reactions to beta-lactam antibiotics in children: are extended challenges needed? J Allergy Clin Immunol Pract. 2019;7(1):265-269.
Van Gasse AL, Ebo DG, Chiriac AM, et al. The limited value of prolonged drug challenges in nonimmediate amoxicillin (clavulanic acid) hypersensitivity. J Allergy Clin Immunol Pract. 2019;7(7):2225-2229.
Chiriac AM, Romano A, Ben Fadhel N, et al. Follow-up of patients with negative drug provocation tests to betalactams. Clin Exp Allergy. 2019;49(5):729-732.
Tonson la Tour A, Michelet M, Eigenmann PA, Caubet JC. Natural history of benign nonimmediate allergy to beta-lactams in children: a prospective study in retreated patients after a positive and a negative provocation test. J Allergy Clin Immunol Pract. 2018;6(4):1321-1326.
Nohra D, Molinari N, Demoly P, Chiriac AM. Data-driven step doses for drug provocation tests to nonsteroidal anti-inflammatory drugs. Allergy. 2020;75(6):1423-1434.
Soria A, Masson N, Vial-Dupuy A, et al. Allergological workup with half-dose challenge in iodinated contrast media hypersensitivity. Allergy. 2019;74(2):414-417.
Perez-Sanchez N, Cornejo-Garcia JA, Bogas-Herrera G, Torres Jaen MJ, Dona DI. Acetylsalicylic acid challenge optimal dose in nonsteroidal anti-inflammatory drugs hypersensitivity diagnosis. Allergy. 2020;75(6):1501-1503.
Trubiano JA, Smibert O, Douglas A, et al. The safety and efficacy of an oral penicillin challenge program in cancer patients: a Multicenter Pilot Study. Open Forum Infect Dis. 2018;5(12):306.
Ramsey A, Mustafa SS, Holly AM, Staicu ML. Direct challenges to penicillin-based antibiotics in the inpatient setting. J Allergy Clin Immunol Pract. 2020;8(7):2294-2301.
Labrosse R, Paradis L, Lacombe-Barrios J, et al. Efficacy and safety of 5-day challenge for the evaluation of nonsevere amoxicillin allergy in children. J Allergy Clin Immunol Pract. 2018;6(5):1673-1680.
Abrams EM, Ben-Shoshan M. Should testing be initiated prior to amoxicillin challenge in children? Clin Exp Allergy. 2019;49(8):1060-1066.
Diaferio L, Chiriac AM, Leoni MC, et al. Skin tests are important in children with beta-lactam hypersensitivity, but may be reduced in number. Pediatr Allergy Immunol. 2019;30(4):462-468.
Mayorga C, Celik G, Rouzaire P, et al. In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2016;71(8):1103-1134.
Ariza A, Torres MJ, Moreno-Aguilar C, Fernandez-Santamaria R, Fernandez TD. Early biomarkers for severe drug hypersensitivity reactions. Curr Pharm Des. 2019;25(36):3829-3839.
Ebo DG, Van Gasse AL, Decuyper II, et al. Acute management, diagnosis, and follow-up of suspected perioperative hypersensitivity reactions in flanders 2001-2018. J Allergy Clin Immunol Pract. 2019;7(7):2194-2204.e2197.
Vitte J, Amadei L, Gouitaa M, et al. Paired acute-baseline serum tryptase levels in perioperative anaphylaxis: an observational study. Allergy. 2019;74(6):1157-1165.
Dona I, Jurado-Escobar R, Perkins JR, et al. Eicosanoid mediator profiles in different phenotypes of nonsteroidal anti-inflammatory drug-induced urticaria. Allergy. 2019;74(6):1135-1144.
van der Poorten MM, Van Gasse AL, Hagendorens MM, et al. Serum specific IgE antibodies in immediate drug hypersensitivity. Clin Chim Acta. 2020;504:119-124.
Fontaine C, Mayorga C, Bousquet PJ, et al. Relevance of the determination of serum-specific IgE antibodies in the diagnosis of immediate beta-lactam allergy. Allergy. 2007;62(1):47-52.
Van Gasse AL, Sabato V, Degerbeck F, et al. Specific IgE to cefazolin: does it benefit diagnosis? J Allergy Clin Immunol Pract. 2019;7(8):2932-2934.
Kalangara J, Potru S, Kuruvilla M. Clinical manifestations and diagnostic evaluation of opioid allergy labels - a review. J Pain Palliat Care Pharmacother. 2019;33(3-4):131-140.
Opstrup MS, Jemec GBE, Garvey LH. Chlorhexidine allergy: on the rise and often overlooked. Curr Allergy Asthma Rep. 2019;19(5):23.
Martin-Serrano A, Mayorga C, Barrionuevo E, et al. Design of an antigenic determinant of cefaclor: chemical structure-IgE recognition relationship. J Allergy Clin Immunol. 2020;145(4):1301-1304.
Li J, Best OG, Rose MA, Green SL, Fulton RB, Fernando SL. Integrating basophil activation tests into evaluation of perioperative anaphylaxis to neuromuscular blocking agents. Br J Anaesth. 2019;123(1):e135-e143.
Mayorga C, Fernandez TD, Montanez MI, Moreno E, Torres MJ. Recent developments and highlights in drug hypersensitivity. Allergy. 2019;74(12):2368-2381.
Mayorga C, Ebo DG, Lang DM, et al. Controversies in drug allergy: In vitro testing. J Allergy Clin Immunol. 2019;143(1):56-65.
Salas M, Fernandez-Santamaria R, Mayorga C, et al. Use of the Basophil Activation Test may reduce the need for drug provocation in amoxicillin-clavulanic allergy. J Allergy Clin Immunol Pract. 2018;6(3):1010-1018.e1012.
Laguna JJ, Bogas G, Salas M, et al. The Basophil Activation Test can be of value for diagnosing immediate allergic reactions to omeprazole. J Allergy Clin Immunol Pract. 2018;6(5):1628-1636.e1622.
Dewachter P, Chollet-Martin S, Mouton-Faivre C, de Chaisemartin L, Nicaise-Roland P. Comparison of Basophil Activation Test and skin testing performances in NMBA allergy. J Allergy Clin Immunol Pract. 2018;6(5):1681-1689.
Barbero N, Fernandez-Santamaria R, Mayorga C, et al. Identification of an antigenic determinant of clavulanic acid responsible for IgE-mediated reactions. Allergy. 2019;74(8):1490-1501.
Molina N, Martin-Serrano A, Fernandez TD, et al. Dendrimeric antigens for drug allergy diagnosis: a new approach for basophil activation tests. Molecules 2018;23(5):E997.
Ebo DG, Baldo BA, Van Gasse AL, et al. Anaphylaxis to sugammadex-rocuronium inclusion complex: An IgE-mediated reaction due to allergenic changes at the sugammadex primary rim. J Allergy Clin Immunol Pract. 2020;8(4):1410-1415.e1413.
Giangrande N, Garcia-Menaya JM, Marcos-Fernandez M, Camara-Hijon C, Bobadilla-Gonzalez P. Anaphylaxis due to macrogol in a laxative solution with a positive basophil activation test. Ann Allergy Asthma Immunol. 2019;123(3):302-304.
Bax HJ, Khiabany A, Stavraka C, et al. Basophil activation test in cancer patient blood evaluating potential hypersensitivity to an anti-tumor IgE therapeutic candidate. Allergy. 2020;75(8):2069-2073.
Fernandez-Santamaria R, Palomares F, Salas M, et al. Expression of the Tim3-galectin-9 axis is altered in drug-induced maculopapular exanthema. Allergy. 2019;74(9):1769-1779.
Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy. 2004;59(8):809-820.
Cabanas R, Calderon O, Ramirez E, et al. Sensitivity and specificity of the lymphocyte transformation test in drug reaction with eosinophilia and systemic symptoms causality assessment. Clin Exp Allergy. 2018;48(3):325-333.
Marques-Mejias MA, Cabanas R, Ramirez E, et al. Lymphocyte Transformation Test (LTT) in allergy to benznidazole: a promising approach. Front Pharmacol. 2019;10:469.
Bellon T, Rodriguez-Martin S, Cabanas R, et al. Assessment of drug causality in Stevens-Johnson syndrome/toxic epidermal necrolysis: Concordance between lymphocyte transformation test and ALDEN. Allergy. 2020;75(4):956-959.
Movsisyan M, Fiandor A, Gonzalez-Munoz M, et al. The lymphocyte transformation test is useful in the diagnosis of fixed drug eruption induced by etoricoxib. J Investig Allergol Clin Immunol. 2019;29(4):307-309.
Trubiano JA, Strautins K, Redwood AJ, et al. The combined utility of ex vivo ifn-gamma release enzyme-linked immunospot assay and in vivo skin testing in patients with antibiotic-associated severe cutaneous adverse reactions. J Allergy Clin Immunol Pract. 2018;6(4):1287-1296 e1281.
Klaewsongkram J, Sukasem C, Thantiworasit P, et al. Analysis of HLA-B allelic variation and IFN-gamma ELISpot responses in patients with severe cutaneous adverse reactions associated with drugs. J Allergy Clin Immunol Pract. 2019;7(1):219-227.e214.
Lin C-Y, Wang C-W, Hui C-y r, et al. Delayed-type hypersensitivity reactions induced by proton pump inhibitors: a clinical and in vitro T-cell reactivity study. Allergy. 2018;73(1):221-229.
Yew PY, Alachkar H, Yamaguchi R, et al. Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2015;50(9):1227-1234.
Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. Clin Transl Allergy. 2015;5:31.
Chang LW, Doan LT, Fields P, Vignali M, Akilov OE. The utility of T-cell clonality in differential diagnostics of acute graft-versus-host disease from drug hypersensitivity reaction. J Invest Dermatol. 2020;140(6):1282-1285.
Oussalah A, Yip V, Mayorga C, et al. Genetic variants associated with T cell-mediated cutaneous adverse drug reactions: a PRISMA-compliant systematic review-an EAACI position paper. Allergy. 2020;75(5):1069-1098.
Zhao Q, Alhilali K, Alzahrani A, et al. Dapsone- and nitroso dapsone-specific activation of T cells from hypersensitive patients expressing the risk allele HLA-B*13:01. Allergy. 2019;74(8):1533-1548.
Thomson PJ, Illing PT, Farrell J, et al. Modification of the cyclopropyl moiety of abacavir provides insight into the structure activity relationship between HLA-B*57:01 binding and T-cell activation. Allergy. 2020;75(3):636-647.
Mockenhaupt M, Wang CW, Hung SI, et al. HLA-B*57:01 confers genetic susceptibility to carbamazepine-induced SJS/TEN in Europeans. Allergy. 2019;74(11):2227-2230.
Genin E, Chen D-P, Hung S-I, et al. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenomics J. 2014;14(3):281-288.
Moutaouakkil Y, Adouani B, Cherrah Y, Lamsaouri J, Bousliman Y. Diagnostic utility of human leukocyte antigen B*15:02 screening in severe carbamazepine hypersensitivity syndrome. Ann Indian Acad Neurol. 2019;22(4):377-383.
Quach C, Galen BT. HLA-B*5801 testing to prevent allopurinol hypersensitivity syndrome: a teachable moment. JAMA Intern Med. 2018;178(9):1260-1261.
Park H-W, Kim DK, Kim S-H, et al. Efficacy of the HLA-B(*)58:01 screening test in preventing allopurinol-induced severe cutaneous adverse reactions in patients with chronic renal insufficiency-a prospective study. J Allergy Clin Immunol Pract. 2019;7(4):1271-1276.
Ng CY, Yeh Y-T, Wang C-W, et al. Impact of the HLA-B(*)58:01 allele and renal impairment on allopurinol-induced cutaneous adverse reactions. J Invest Dermatol. 2016;136(7):1373-1381.
Shim J-S, Yun J, Kim M-Y, et al. The presence of HLA-B75, DR13 homozygosity, or DR14 additionally increases the risk of allopurinol-induced severe cutaneous adverse reactions in HLA-B*58:01 carriers. J Allergy Clin Immunol Pract. 2019;7(4):1261-1270.
Konvinse KC, Trubiano JA, Pavlos R, et al. HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. J Allergy Clin Immunol. 2019;144(1):183-192.
Nakkam N, Gibson A, Mouhtouris E, et al. Cross-reactivity between vancomycin, teicoplanin, and telavancin in patients with HLA-A *32:01-positive vancomycin-induced DRESS sharing an HLA class II haplotype. J Allergy Clin Immunol. 2020.
Blanca M, Oussalah A, Cornejo-Garcia JA, et al. GNAI2 variants predict nonsteroidal anti-inflammatory drug hypersensitivity in a genome-wide study. Allergy 2020;75(5):1250-1253.